Srdan Verstovsek, MD, PhD

Articles

Dr. Verstovsek on Real-World Survival Data With Ruxolitinib in Myelofibrosis

May 10th 2021

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Dr. Verstovsek on the Efficacy of Ruxolitinib Plus CPI-0610 in Myelofibrosis

May 3rd 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Dr. Verstovsek on the Potential Utility of Luspatercept in Myelofibrosis

April 15th 2021

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

Dr. Verstovsek on the Role of Prognostication in Myelofibrosis

April 7th 2021

Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.

Dr. Verstovsek on the Use of Luspatercept to Treat Anemia Associated With Myelofibrosis

February 16th 2021

Srdan Verstovsek, MD, PhD, discusses the use of luspatercept to treat anemia associated with myelofibrosis.

Dr. Verstovsek on the Role of Ruxolitinib in Myelofibrosis

December 16th 2020

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Dr. Verstovsek on the Results of the PV-AIM trial in Polycythemia Vera

December 5th 2020

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

Dr. Verstovsek on the Different Phases of MPNs

October 6th 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

August 29th 2020

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Dr. Verstovsek on the Rationale Behind Treating Myelofibrosis With CPI-0610/Ruxolitinib

July 13th 2020

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.